Swainsonine
|
WikiDoc Resources for Swainsonine |
|
Articles |
|---|
|
Most recent articles on Swainsonine Most cited articles on Swainsonine |
|
Media |
|
Powerpoint slides on Swainsonine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Swainsonine at Clinical Trials.gov Clinical Trials on Swainsonine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Swainsonine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Swainsonine Discussion groups on Swainsonine Patient Handouts on Swainsonine Directions to Hospitals Treating Swainsonine Risk calculators and risk factors for Swainsonine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Swainsonine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Swainsonine is a potent inhibitor of Golgi alpha-mannosidase II, immunomodulator and potential anticancer agent. Disruption of Golgi alpha-mannosidase II with swainsonine induces hybrid-type glycans. These glycans have a Man5GlcNAc2 core with processing on the 3-arm that resembles so-called complex-type glycans.
The pharmacological properties of this product have not been fully investigated.
Handling Instructions
- Soluble in water (10 mg/1 ml) and ethanol
- Use caution when handling.
- This product must not be used in humans
- Store between 0-4 ˚C for up to 1 year
- Store or 20 ˚C for up to 3 months
- Disposal: A
References
- Swainsonine at Logan Natural Products